“The right price for vaccines must take into account the value of their collective creation but also the fact that they are essential goods produced collectively to safeguard the vulnerable—no matter where they live.” Mariana Mazzucato & Els Torreele PDF more
Why government must negotiate a better deal for publicly funded research. more
In recent days, my name has been mentioned by John McDonnell in relation to policies he and Jeremy Corbyn have been floating relating to the patent box policy and funding of medical innovation in the UK. I should say first off that I was once a member of Labour’s Economic Advisory Committee (EAC) performing a similar role to that which I have for Nicola Sturgeon in her Council of Economic Advisors (CEA) and, in various ways, with other policy makers worldwide. And although Labour’s EAC is not currently operating, I actually never discussed pharmaceutcal more
The current debate about medical innovation is characterized by a poor understanding of, and many myths around, the drivers behind innovation, in particular the respective roles of public and private actors in the innovation process. more
Global pharmaceutical companies are dodging the risks by more
Mazzucato, M. and Parris, S. (2014) more
Mazzucato M. et al (2010) “The limits to the 3% R&D target in Europe 2020: the roles of institutions, industries, and business-government complementarities in achieving equitable and stable growth.” more
“US healthcare reform is not an act of meddling” more
What is needed in the pharmaceutical industry is more radical innovation, including radical thinking about the ‘innovation division of labour, writes Mazzucato. more
The Evolution of Firm Growth Dynamics in the US Pharmaceutical Industry more